Moderna, Merck Revive mRNA Hopes With Melanoma Success

Moderna and Merck announced that a personalized vaccine developed jointly by the two companies reduced melanoma recurrence in a late-stage clinical trial. The vaccine is designed to be tailored to individual patients' tumors. Results from the trial were presented at a medical conference, according to Bloomberg.

Next story